AMENDMENT TO CONSULTING AGREEMENT

Exhibit 10.1

AMENDMENT TO CONSULTING AGREEMENT

This Amendment to Consulting Agreement (the “Amendment”), effective as of December 16^th, 2021 (the “Effective Date”), is by and between Variation Biotechnologies Inc., a corporation incorporated pursuant to the laws of Canada (the “Company”) having an address of 000 Xxxx Xxxx Xxxx Xxxx, Xxxxxx, Xxxxxxx X0X 0X0 and X. Xxxx-Xxxxxx Professional Corporation (Ontario corporation number 002356634) having an address of 000 Xxxxxx Xxxxxxxx, Xxxxxx, Xxxxxxx X0X 0X0 (“Consultant”). The Consultant and Company are sometimes referred to as a “Party” and are collectively referred to as the “Parties”.

WHEREAS, the Company and Consultant are parties to a certain Consulting Agreement dated July 1, 2016, amended as of January 1, 2017, amended January 1, 2018, amended January 1, 2019, January 1, 2020, and further amended as of January 1, 2021 (the “Consulting Agreement”);

AND WHEREAS, the Consultant and the Company wish to amend the Consulting Agreement on the terms and conditions set out in this Amendment;

NOW THEREFORE, in consideration of the mutual covenants contained herein, the Parties agree as follows:

1. Amendment to Appendix C. As of the Effective Date, Appendix C – Performance Incentives of the Consulting Agreement shall be amended to include paragraph 3 in the version of Appendix C attached as Schedule A to this Amendment.

2. Consulting Agreement to Remain in Full Effect. Except as amended by this Amendment, the Consulting Agreement shall continue to be in full force and effect, without amendment, and is hereby ratified and confirmed. The Consulting Agreement shall henceforth be read and construed in conjunction with this Amendment.

3. Governing Law. This Amendment shall be governed by and construed in accordance with the laws of the Province of Ontario and the federal laws of Canada applicable therein.

4.  Further Assurances. Each Party shall do such further acts and execute such further documents as may be required to give effect to this Amendment and carry out the intent thereof.

5.  Binding Effect. This Amendment shall be binding on and inure to the benefit of the Parties and their respective successors and assigns.

6. Execution and Counterparts. This Amendment may be executed in counterparts, including counterpart signature pages or counterpart facsimile or scanned signature pages (each of which shall be deemed an original), all of which together shall constitute one and the same instrument.

(Signature page follows.)

IN WITNESS WHEREOF, the Parties hereto have caused this Amendment to be duly executed by their respective authorized officers as of the Effective Date.

	VARIATION BIOTECHNOLOGIES INC.
		/s/ Xxxx Xxxxxx
	Name:	Xxxx Xxxxxx
	Title:	Chief Executive Officer
	X. XXXX-XXXXXX PROFESSIONAL CORPORATION
		/s/ Xx. Xxxxxxxxx Xxxx-Xxxxxx
	Name:	Xx. Xxxxxxxxx Xxxx-Xxxxxx
	Title:	President

Schedule A

Appendix C – Performance Incentives

1.	Bonus payable as of January 31, 2021 – CAD $265,500
2.	The Company shall cause VBI Vaccines Inc., a British Columbia corporation (the “Parent”) to grant to Xxxxxxxxx Xxxx-Xxxxxx, as designee of Consultant, 500,000 stock options (the “Options”), each Option exercisable for one common share of Parent, to be granted effective as of January 27, 2021, which was the date on which the board of directors of Parent approved such grant, and to be subject to the provisions of the Plan. Conditions regarding the Options and their exercise, including the exercise price, the term of the Options and the timing of vesting shall be set out in an Option Agreement between the Parent and Xxxxxxxxx Xxxx-Xxxxxx. The common shares issuable upon exercise of the Options shall bear the appropriate legend to indicate such shares are “control securities” as defined in General Instruction C.1(a) of Form S-8.
3.	Additional bonus, as a result of the successful U.S. FDA approval of PreHevbrio™ on November 30, 2021, payable as of December 16, 2021 – CAD $50,000